BR0210645A - Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto. - Google Patents

Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto.

Info

Publication number
BR0210645A
BR0210645A BR0210645-0A BR0210645A BR0210645A BR 0210645 A BR0210645 A BR 0210645A BR 0210645 A BR0210645 A BR 0210645A BR 0210645 A BR0210645 A BR 0210645A
Authority
BR
Brazil
Prior art keywords
alkyl
compound
nhc
heteroaryl
cycloalkyl
Prior art date
Application number
BR0210645-0A
Other languages
English (en)
Inventor
Nicole Corine Renee Straten
Rudolf Gijsbertus Van Someren
Jurgen Schulz
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0210645A publication Critical patent/BR0210645A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

"COMPOSTO DERIVADO DE TETRAIDROQUINOLINA, COMPOSIçãO FARMACêUTICA, E, USO DO COMPOSTO". A presente invenção refere-se a derivados de tetraidroquinolina, tendo a fórmula geral (I) ou um seu sal farmaceuticamente aceitável, em que R^ 1^ é formila, (1-6C)alquilcarbonila ou (1-6C)alquilsulfonila; R^ 2^ e R^ 3^ são H ou (1-4C)alquila; R^ 4^ é fenila; R^ 5^ é (14C)alquila; Y-X é (CO)-O, (SO)~ 2~-O, NHC(O)-O, NHC(S)-O, OC(O)-O, ligação-O, C(O)-NH, S(O)~ 2~-NH, NHC(O)-NH, NHC(S)-NH, OC(O)-NH, ligação-NH, NH-C(O), O-C(O), NH-S(O)~ 2~ OU O-S(0)~ 2~ OU Y-X é uma ligação; R^ 6^ é H, trifluorometila, (1-6C)alquila, 1- ou 2-adamantil(1-4C)alquila, (26)alquenila, (3-9C)heteroarila, (3-6C)cicloalquila, (2-6C)heterocicloalquila, (1-4C)alquiltio(1-4C)alquila, (6-10C)aril(1-4C)alquila, (3-9C)heteroaril(14C)alquila, (3-6C)cicloalquil(1-4C)alquila, (2-6C)heterocicloalquil(14C)alquila, R^ 8^, R^ 9^-aminocarbonil(1-4C)alquila, R^ 8^, R^ 9^-amino(1-4C)alquila, R^ 8^-oxicarbonil (1-4C)alquila, R^ 8^-oxi(1-4C)alquila, R^ 8^-carbonil(1-4C)alquila ou (6-10C)arila; R^ 7^ é H, (1-4C)alquila, (1-4C)alcóxi, halogênio, trifluorometila, ciano, nitro, hidroxila; e R^ 8^ e/ou R^ 9^ é H, (1-4C)alquila, (2-4C)alquenila, (2-4C)alquinila, (6-10C) arila, (3-9C)heteroarila, (6-10C) aril(14C)alquila, (3-9C)heteroaril(1-4C)alquila, (3-6C)cicloalquil(1-4C)alquila, (26C)heterocicloalquil(1-4C)alquila, (1-4C)(di)alquilamino(1-4C)alquila, (14C)alcóxi(1-4C)alquila, (1-4C)alquiltio(1-4C)alquila, (1-4C)alquilcarbonilamino(1-4é)alquila, (1-4C)alcoxicarbonil(1-4C)alquila, (1-4C)alcoxicarbonilamino(1 -4C)alquila, (3-6C)cicloalquila, (2-6C)heterocicloalquila, ou R^ 8^ e R^ 9^ podem ser unidos em um anel (2-6C)heterocicloalquila. A presente invenção também refere-se a composições farmacêuticas compreendendo ditos derivados e o uso destes derivados para controlar a fertilidade.
BR0210645-0A 2001-07-02 2002-06-25 Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto. BR0210645A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202531 2001-07-02
PCT/EP2002/007053 WO2003004028A1 (en) 2001-07-02 2002-06-25 Tetrahydroquinoline derivatives

Publications (1)

Publication Number Publication Date
BR0210645A true BR0210645A (pt) 2004-10-05

Family

ID=8180574

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210645-0A BR0210645A (pt) 2001-07-02 2002-06-25 Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto.

Country Status (32)

Country Link
US (2) US8058441B2 (pt)
EP (1) EP1406628B1 (pt)
JP (1) JP4523273B2 (pt)
KR (1) KR100908468B1 (pt)
CN (1) CN1261099C (pt)
AR (1) AR034669A1 (pt)
AT (1) ATE319451T1 (pt)
AU (1) AU2002317848B2 (pt)
BR (1) BR0210645A (pt)
CA (1) CA2452606C (pt)
CY (1) CY1106087T1 (pt)
CZ (1) CZ20042A3 (pt)
DE (1) DE60209734T2 (pt)
DK (1) DK1406628T3 (pt)
EC (1) ECSP034932A (pt)
ES (1) ES2260458T3 (pt)
HK (1) HK1061810A1 (pt)
HR (1) HRP20031080A2 (pt)
HU (1) HUP0400390A2 (pt)
IL (1) IL159288A0 (pt)
IS (1) IS2418B (pt)
MX (1) MXPA03011908A (pt)
NO (1) NO325516B1 (pt)
NZ (1) NZ530198A (pt)
PE (1) PE20030273A1 (pt)
PL (1) PL367638A1 (pt)
PT (1) PT1406628E (pt)
RU (1) RU2347570C2 (pt)
SA (1) SA02230260B1 (pt)
SK (1) SK286759B6 (pt)
WO (1) WO2003004028A1 (pt)
ZA (1) ZA200309921B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260458T3 (es) 2001-07-02 2006-11-01 Akzo Nobel N.V. Derivados de tetrahidroquinolina.
ES2316777T3 (es) * 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
FR2836620B1 (fr) * 2002-02-28 2004-04-16 Snecma Services Instrument de projection thermique
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
RU2350354C2 (ru) * 2003-05-29 2009-03-27 Астразенека Аб ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТАГОНИСТ Р2Х7 РЕЦЕПТОРА И ФАКТОР НЕКРОЗА ОПУХОЛИ α
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
UA92007C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
DK1879866T3 (da) 2005-05-04 2011-06-06 Organon Nv Dihydropyridinderivater
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
UA92009C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
US7687623B2 (en) 2005-05-12 2010-03-30 Wyeth Llc Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
CA2609714A1 (en) 2005-06-09 2006-12-21 Wyeth Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
US20070060573A1 (en) * 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
EP1912970A2 (en) * 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
WO2008071453A1 (en) * 2006-12-13 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 1,2-diarylacetylene derivatives of acyltryptophanols
EP1932831A1 (en) * 2006-12-13 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylacetylene Derivatives of Acyltryptophanols
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
WO2008114002A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
TW200918058A (en) 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
BR112013007907A2 (pt) * 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
US8546427B2 (en) * 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
WO2016018553A1 (en) * 2014-07-30 2016-02-04 Henkel IP & Holding GmbH Cure accelerators for anaerobic curable compositions
WO2019089412A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2686182A (en) 1950-12-07 1954-08-10 Basf Ag O-hydroxy-dihydro-quinoline carboxylic acids
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
NZ300739A (en) * 1994-12-22 2000-05-26 Ligand Pharm Inc Steroid receptor modulator compounds
JP4511042B2 (ja) * 1998-08-07 2010-07-28 メルク セローノ ソシエテ アノニム 不妊症の治療のためのｆｓｈ模倣物
JP2000143636A (ja) * 1998-09-02 2000-05-26 Sumitomo Pharmaceut Co Ltd アミノ誘導体
US6200963B1 (en) 1999-03-31 2001-03-13 American Home Products Corporation Aryl sulfonic acids as FSH antagonists
ES2260458T3 (es) 2001-07-02 2006-11-01 Akzo Nobel N.V. Derivados de tetrahidroquinolina.
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
US20120202996A1 (en) 2012-08-09
PT1406628E (pt) 2006-06-30
HUP0400390A2 (hu) 2004-09-28
CN1261099C (zh) 2006-06-28
SA02230260B1 (ar) 2007-03-25
SK16342003A3 (sk) 2004-07-07
RU2347570C2 (ru) 2009-02-27
IS7071A (is) 2003-12-11
IS2418B (is) 2008-10-15
KR20040030714A (ko) 2004-04-09
NO20035763L (no) 2003-12-29
CA2452606A1 (en) 2003-01-16
PE20030273A1 (es) 2003-03-21
MXPA03011908A (es) 2004-06-03
IL159288A0 (en) 2004-06-01
CN1529601A (zh) 2004-09-15
SK286759B6 (sk) 2009-05-07
AR034669A1 (es) 2004-03-03
EP1406628A1 (en) 2004-04-14
NZ530198A (en) 2005-11-25
ZA200309921B (en) 2005-03-22
ECSP034932A (es) 2004-02-26
WO2003004028A1 (en) 2003-01-16
RU2004102693A (ru) 2005-06-27
CA2452606C (en) 2011-09-13
JP4523273B2 (ja) 2010-08-11
EP1406628B1 (en) 2006-03-08
HK1061810A1 (en) 2004-10-08
CY1106087T1 (el) 2011-06-08
NO325516B1 (no) 2008-06-02
DE60209734D1 (de) 2006-05-04
DK1406628T3 (da) 2006-07-03
US20040236109A1 (en) 2004-11-25
ES2260458T3 (es) 2006-11-01
ATE319451T1 (de) 2006-03-15
DE60209734T2 (de) 2006-08-31
PL367638A1 (en) 2005-03-07
US8258293B2 (en) 2012-09-04
JP2004535456A (ja) 2004-11-25
AU2002317848B2 (en) 2006-08-31
HRP20031080A2 (en) 2004-04-30
CZ20042A3 (en) 2004-04-14
US8058441B2 (en) 2011-11-15
KR100908468B1 (ko) 2009-07-21

Similar Documents

Publication Publication Date Title
BR0210645A (pt) Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto.
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
EP1939175A4 (en) SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
IL154350A (en) Phenylalanine derivatives and pharmaceutical preparations containing them
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
EP1243582A4 (en) CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
AUPR213700A0 (en) Antiviral agents
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
AU2002257587A1 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
AU4661900A (en) Noscapine derivatives as adjuvant compositions and methods of use thereof
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
EP1886691A3 (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
CO5271717A1 (es) Combinaciones farmaceuticas
WO2004014389A8 (en) 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
AU2003226765A1 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
DK0880520T3 (da) Benzo[c]quinolinderivater, deres fremstilling af anvendelse som 5-alfa-reduktaseinhibitorer
DE60222131D1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE60217315D1 (de) Pharmazeutische zusammensetzungen von rapamycines
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
AR036408A1 (es) Tieno[2,3-d]pirimidinas sustituidas con glicina con actividad agonista combinada de lh y fsh
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
BR0213463A (pt) Composições farmacêuticas contendo macrólidos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.